Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
Sign Up to like & getrecommendations! Published in 2023 at "Pulmonary Circulation"
DOI: 10.1002/pul2.12224
Abstract: Abstract Continuous subcutaneous (SubQ) treprostinil is an effective therapy for pediatric patients diagnosed with pulmonary hypertension (PH). To date, the clinical characteristics and factors associated with failure to tolerate this therapy have not been described.… read more here.
Keywords: failure tolerate; continuous subcutaneous; subq treprostinil; treprostinil ... See more keywords
Inpatient Initiation of Oral Treprostinil in an Academic Medical System
Sign Up to like & getrecommendations! Published in 2020 at "Cardiovascular Drugs and Therapy"
DOI: 10.1007/s10557-020-06992-0
Abstract: Purpose Clinicians may transition patients on parenteral or inhaled prostacyclins to oral treprostinil for ease of use or to avoid adverse effects related to parenteral therapy. However, few data are available to guide these transitions… read more here.
Keywords: system; oral treprostinil; inpatient initiation; initiation oral ... See more keywords
Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure
Sign Up to like & getrecommendations! Published in 2017 at "Chest"
DOI: 10.1016/j.chest.2017.04.188
Abstract: BACKGROUND: Prostacyclins improve symptoms and survival in pulmonary arterial hypertension (PAH). In response to risks associated with external delivery systems, an implantable IV infusion system was developed. A multicenter, prospective, single‐arm, clinical trial (DelIVery for… read more here.
Keywords: catheter; system; procedure; implantation ... See more keywords
TRANSITION FROM SELEXIPAG TO ORAL TREPROSTINIL IN A PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
Sign Up to like & getrecommendations! Published in 2018 at "Chest"
DOI: 10.1016/j.chest.2018.08.923
Abstract: Prostacyclins are the mainstay treatment for patients with severe pulmonary arterial hypertension. This case highlights the transition from selexipag to oral treprostinil. Our patient improved both subjectively and objectively. Cardiac output and index, as measured… read more here.
Keywords: selexipag oral; oral treprostinil; arterial hypertension; pulmonary arterial ... See more keywords
Lowering of mean pulmonary arterial pressure is a prognostic marker in pulmonary hypertension patients treated with subcutaneous treprostinil
Sign Up to like & getrecommendations! Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.2255
Abstract: Treprostinil (TRE), a prostacyclin analog, is effective for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH). We hypothesized that change of hemodynamics is of prognostic value. In our prospective registry we… read more here.
Keywords: pulmonary hypertension; patients treated; pulmonary arterial; hypertension ... See more keywords
Rapid Switch from Subcutaneous to Intravenous Treprostinil in Precapillary Pulmonary Hypertension by Pump Implantation.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Cardiovascular Pharmacology"
DOI: 10.1097/fjc.0000000000000933
Abstract: Limited data is available on the transition from subcutaneous to intravenous prostacyclin in precapillary pulmonary hypertension. We performed a retrospective analysis of all patients who were switched from subcutaneous to intravenous treprostinil with an implantable… read more here.
Keywords: treprostinil; intravenous treprostinil; subcutaneous intravenous; implantation ... See more keywords
Treprostinil for persistent pulmonary hypertension of the newborn, with early onset sepsis in preterm infant
Sign Up to like & getrecommendations! Published in 2017 at "Medicine"
DOI: 10.1097/md.0000000000007303
Abstract: Rationale: Persistent pulmonary hypertension of the newborn (PPHN) is a syndrome of failed circulatory adaptation at birth with persisting increased pulmonary vascular resistance that is associated with high mortality rates especially in preterm infants. Patient… read more here.
Keywords: persistent pulmonary; early onset; pulmonary hypertension; onset sepsis ... See more keywords
Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
Sign Up to like & getrecommendations! Published in 2019 at "Pulmonary Circulation"
DOI: 10.1177/2045894019856471
Abstract: Treprostinil, a prostacyclin analogue, is approved for the treatment of pulmonary arterial hypertension (PAH) in adults. Transition from parenteral to oral treprostinil has been successfully accomplished in adults with PAH but not in children. In… read more here.
Keywords: therapy; oral treprostinil; transition; arterial hypertension ... See more keywords
Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension
Sign Up to like & getrecommendations! Published in 2020 at "Pulmonary Circulation"
DOI: 10.1177/2045894019898032
Abstract: Prostacyclins are the mainstay treatment for patients with severe pulmonary arterial hypertension. This case highlights the transition from selexipag to oral treprostinil. Our patient improved both subjectively and objectively. Cardiac output and index, as measured… read more here.
Keywords: selexipag oral; oral treprostinil; arterial hypertension; pulmonary arterial ... See more keywords
An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
Sign Up to like & getrecommendations! Published in 2017 at "BMC Pulmonary Medicine"
DOI: 10.1186/s12890-017-0474-7
Abstract: BackgroundSubcutaneous treprostinil is a prostacyclin analogue used to treat pulmonary arterial hypertension (PAH). Due to local pain it can cause a deterioration of heart related quality of life (HRQoL) or even abandonment of treatment. The… read more here.
Keywords: implantable pump; treatment; pulmonary arterial; treprostinil ... See more keywords
Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells
Sign Up to like & getrecommendations! Published in 2018 at "PLoS ONE"
DOI: 10.1371/journal.pone.0205195
Abstract: Treprostinil is applied for pulmonary arterial hypertension (PAH) therapy. However, the mechanism by which the drug achieves its beneficial effects in PAH vessels is not fully understood. This study investigated the effects of treprostinil on… read more here.
Keywords: arterial smooth; pulmonary arterial; muscle cells; smooth muscle ... See more keywords